E-LIB Suche - Ergebnisse für: GOEMANS, N

1

C.2 SUNFISH parts 1 and 2: 4-year efficacy and safety data ..:

Mah, JK ; Oskoui, M ; Day, JW...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 50 (2023) s2 - p. S51-S52 , 2023

Link: https://doi.org/10.1017/..

2

P40 Long-term effects of corticosteroid treatment in DMD: d..:

Ikelaar, N. ; van der Holst, M. ; Meijer - Krom, Y....
Neuromuscular Disorders. 33 (2023) - p. S107 , 2023

Link: https://doi.org/10.1016/..

3

PCR28 Characterization of Patients with Duchenne Muscular D..:

Muntoni, F. ; Goemans, N. ; Posner, N....
Value in Health. 26 (2023) 6 - p. S316-S317 , 2023

Link: https://doi.org/10.1016/..

4

P37 Givinostat in DMD: results of the Epidys Study with par..:

Mercuri, E. ; Brogna, C. ; Mah, J....
Neuromuscular Disorders. 33 (2023) - p. S106 , 2023

Link: https://doi.org/10.1016/..

5

P140 Predicting long-term trajectories of the North Star Am..:

Muntoni, F. ; Signorovitch, J. ; Goemans, N....
Neuromuscular Disorders. 33 (2023) - p. S82 , 2023

Link: https://doi.org/10.1016/..

6

P138 Development and evaluation of a composite time-to-prog..:

McDonald, C. ; Muntoni, F. ; Marden, J....
Neuromuscular Disorders. 33 (2023) - p. S82 , 2023

Link: https://doi.org/10.1016/..

7

P.67 Development and evaluation of a time to event endpoint..:

McDonald, C. ; Muntoni, F. ; Marden, J....
Neuromuscular Disorders. 32 (2022) - p. S69 , 2022

Link: https://doi.org/10.1016/..

8

P.126 Genotype-unmatched controls are feasible for drug dev..:

Muntoni, F. ; Signorovitch, J. ; Frean, M....
Neuromuscular Disorders. 32 (2022) - p. S100 , 2022

Link: https://doi.org/10.1016/..

9

O.13 Givinostat in DMD: results of the Epidys Study:

Mercuri, E. ; Vilchez, J. ; Boespflug-Tanguy, O....
Neuromuscular Disorders. 32 (2022) - p. S95-S96 , 2022

Link: https://doi.org/10.1016/..

10

P.114 SUNFISH parts 1 and 2: 3-year efficacy and safety of ..:

Day, J. ; Deconinck, N. ; Mazzone, E....
Neuromuscular Disorders. 32 (2022) - p. S89-S90 , 2022

Link: https://doi.org/10.1016/..

11

FP.27 Results of a double-blind cross-over trial of vamorol..:

Hoffman, E. ; Guglieri, M. ; Clemens, P....
Neuromuscular Disorders. 32 (2022) - p. S98 , 2022

Link: https://doi.org/10.1016/..

12

Gait stage classification for children with Duchenne muscul..:

Vandekerckhove, I. ; Verreydt, I. ; Van Grinderbeek, M....
Gait & Posture. 97 (2022) - p. S239-S241 , 2022

Link: https://doi.org/10.1016/..

13

P.63 Comparison of brain volume reduction in boys with Duch..:

Geuens, S. ; Van Dessel, J. ; Lemiere, J....
Neuromuscular Disorders. 32 (2022) - p. S68 , 2022

Link: https://doi.org/10.1016/..

14

P.65 Consistency of changes in percent-predicted forced vit..:

Goemans, N. ; McDonald, C. ; Muntoni, F....
Neuromuscular Disorders. 32 (2022) - p. S68-S69 , 2022

Link: https://doi.org/10.1016/..

15

P.133 Daily regimens of prednisone, deflazacort and vamorol..:

McDonald, C. ; Henricson, E. ; Leinonen, M....
Neuromuscular Disorders. 32 (2022) - p. S102 , 2022

Link: https://doi.org/10.1016/..